Dapagliflozin Found to Lower the Risk for Worsening HF, CV Death in HF With Reduced Ejection Fraction, Regardless of T2DM Status
Dapagliflozin was found to lower the risk for worsening heart failure or death in patients with heart failure and reduced ejection fraction, and with or without diabetes compared with placebo.
